Literature DB >> 20109982

Patient perception of symptoms and quality of life following ablation in patients with supraventricular tachycardia.

Kathryn A Wood1, Anita L Stewart, Barbara J Drew, Melvin M Scheinman, Erika S Froëlicher.   

Abstract

OBJECTIVES: It remains unclear which symptom experiences and aspects of quality of life (QOL) change after ablation in patients with supraventricular tachycardia (SVT). To determine how patient perceptions of symptoms and QOL change after ablation, we used a single group pretest-posttest design.
METHODS: Patients with SVT (n=52; mean age 41+/-17 years; 65% female) completed generic and disease-specific measures at baseline and 1 month after ablation.
RESULTS: Significant improvement after ablation was noted on virtually all measures (P <.05). Patients reported decreases from baseline regarding frequency and duration of episodes, number of symptoms, and impact of SVT on routine activities. All symptoms decreased in prevalence; however, no symptoms were completely eliminated at 1-month follow-up. Women, more so than men, reported larger changes in symptom and QOL scores after ablation.
CONCLUSIONS: Despite the small sample, statistically significant improvement was found after ablation in a variety of patients with different symptoms and QOL indices. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20109982      PMCID: PMC2817962          DOI: 10.1016/j.hrtlng.2009.04.001

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  21 in total

1.  Gender differences in symptom experiences of patients with acute coronary syndromes.

Authors:  Wan Chen; Susan L Woods; Diana J Wilkie; Kathleen A Puntillo
Journal:  J Pain Symptom Manage       Date:  2005-12       Impact factor: 3.612

Review 2.  Efficacy and safety in clinical trials in cardiovascular disease.

Authors:  Jay N Cohn
Journal:  J Am Coll Cardiol       Date:  2006-07-12       Impact factor: 24.094

3.  Frequency of disabling symptoms in supraventricular tachycardia.

Authors:  K A Wood; B J Drew; M M Scheinman
Journal:  Am J Cardiol       Date:  1997-01-15       Impact factor: 2.778

4.  The impact of supraventricular tachycardias on driving ability in patients referred for radiofrequency catheter ablation.

Authors:  Ulla Walfridsson; Håkan Walfridsson
Journal:  Pacing Clin Electrophysiol       Date:  2005-03       Impact factor: 1.976

5.  Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs.

Authors:  M N Bathina; S Mickelsen; C Brooks; J Jaramillo; T Hepton; F M Kusumoto
Journal:  Am J Cardiol       Date:  1998-09-01       Impact factor: 2.778

6.  Unrecognized paroxysmal supraventricular tachycardia. Potential for misdiagnosis as panic disorder.

Authors:  T J Lessmeier; D Gamperling; V Johnson-Liddon; B S Fromm; R T Steinman; M D Meissner; M H Lehmann
Journal:  Arch Intern Med       Date:  1997-03-10

7.  Quality of life before and after radiofrequency catheter ablation in patients with drug refractory atrioventricular nodal reentrant tachycardia.

Authors:  M S Larson; K McDonald; C Young; R Sung; M A Hlatky
Journal:  Am J Cardiol       Date:  1999-08-15       Impact factor: 2.778

8.  Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias.

Authors:  R S Bubien; S M Knotts-Dolson; V J Plumb; G N Kay
Journal:  Circulation       Date:  1996-10-01       Impact factor: 29.690

Review 9.  Gender bias in the diagnosis and treatment of coronary artery disease.

Authors:  T A Beery
Journal:  Heart Lung       Date:  1995 Nov-Dec       Impact factor: 2.210

10.  Supraventricular tachycardia and the struggle to be believed.

Authors:  Kathryn A Wood; Carolyn L Wiener; Jeanie Kayser-Jones
Journal:  Eur J Cardiovasc Nurs       Date:  2007-04-03       Impact factor: 3.908

View more
  6 in total

1.  Symptom challenges after atrial fibrillation ablation.

Authors:  Kathryn A Wood; Angel H Barnes; Sudeshna Paul; Kristina A Hines; Kevin P Jackson
Journal:  Heart Lung       Date:  2017-09-18       Impact factor: 2.210

2.  Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias: Endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE).

Authors:  Demosthenes G Katritsis; Giuseppe Boriani; Francisco G Cosio; Pierre Jais; Gerhard Hindricks; Mark E Josephson; Roberto Keegan; Bradley P Knight; Karl-Heinz Kuck; Deirdre A Lane; Gregory Yh Lip; Helena Malmborg; Hakan Oral; Carlo Pappone; Sakis Themistoclakis; Kathryn A Wood; Kim Young-Hoon; Carina Blomström Lundqvist
Journal:  Arrhythm Electrophysiol Rev       Date:  2016

3.  Long-Term Patient Experience Following Acutely Successful Ablation of Supraventricular Tachycardia Substrate in Children.

Authors:  Michael A Fremed; Eric S Silver; Anna Joong; Martin Liberman; Leonardo Liberman
Journal:  Pediatr Cardiol       Date:  2020-09-26       Impact factor: 1.655

4.  Variations in follow-up after atrial fibrillation ablation.

Authors:  Kathryn A Wood; Angel H Barnes
Journal:  J Am Assoc Nurse Pract       Date:  2020-05-06       Impact factor: 1.165

5.  Impact of Radiofrequency Ablation and Antiarrhythmic Medications on the Quality of Life of Patients with Supraventricular Tachycardias: Preliminary Validation of the Greek Version of the Umea22 (U22) Questionnaire.

Authors:  Philippe-Richard Domeyer; Smaragda Ch Giannakidou; Panagiota Kyriakou; Vasiliki Katsari; Antonios P Antoniadis; Ioannis K Lagos; Nikolaos Fragakis; Agoritsa Varaklioti; Vassilios P Vassilikos
Journal:  Biomed Res Int       Date:  2018-10-09       Impact factor: 3.411

6.  Health care centre and emergency department utilization by patients with episodes of tachycardia.

Authors:  Ann-Katrin Nordblom; Gabriella Norberg Boysen; Mia Berglund; Anna Kjellsdotter
Journal:  BMC Cardiovasc Disord       Date:  2022-03-23       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.